1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Angiospasm, Intracranial in 35 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 9.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 9.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAH patients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale)." | 8.88 | Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. ( He, GH; Liu, GJ; Liu, Y; Luo, GJ; Wang, XL; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ, 2012) |
| "The incidence of convulsion and associated factors were retrospectively analyzed in 23 patients with symptomatic cerebral vasospasm following subarachnoid hemorrhage (SAH) who underwent a total of 31 intra-arterial infusion of fasudil hydrochloride (IAFH) procedures in 49 vessels." | 7.76 | Convulsion during intra-arterial infusion of fasudil hydrochloride for the treatment of cerebral vasospasm following subarachnoid hemorrhage. ( Enomoto, Y; Iwama, T; Yamada, K; Yoshimura, S, 2010) |
| "The cerebral circulatory dynamics were evaluated before and after intra-arterial administration of fasudil hydrochloride in 20 patients with angiographic vasospasm after subarachnoid hemorrhage (SAH)." | 7.73 | Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage - analysis of time-density curve with digital subtraction angiography. ( Hayashi, M; Iwabuchi, S; Samejima, H; Ueda, M; Uehara, H; Yokouchi, T, 2006) |
| "The authors report a case of convulsion during intra-arterial selective infusion of fasudil hydrochloride (FSD) for treatment of vasospasm following subarachnoid hemorrhage (SAH)." | 7.72 | [A case of convulsion during selective intra-arterial infusion of fasudil hydrochloride for treatment of vasospasm following subarachnoid hemorrhage]. ( Date, I; Nakashimia, H; Ohmoto, T; Ono, S; Sasahara, W; Sugiu, K; Tokunaga, K, 2004) |
| "To investigate the safety and efficacy of liposomal fasudil in a sustained-release form for the prevention of cerebral vasospasm after subarachnoid hemorrhage (SAH)." | 7.71 | Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. ( Ishida, T; Kiwada, H; Meguro, T; Takanashi, Y; Yamamoto, I; Zhang, JH, 2001) |
| " The occurrence of adverse events, occurrence of low density areas associated with vasospasm on computed tomography, absence of symptomatic vasospasm, and poor clinical outcomes associated with vasospasm were compared between the fasudil and fasudil plus ozagrel groups." | 5.35 | Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. ( Satoh, S; Seto, M; Shibuya, M; Sugiyama, H; Suzuki, Y; Takakura, K, 2008) |
| "This new approach for cerebral vasospasm may have significant potential for use in the clinical setting." | 5.31 | Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats. ( Allen, TM; Ishida, T; Kirchmeier, MJ; Meguro, T; Takanashi, Y; Zhang, JH, 2001) |
| "since October 1999, nicardipine pellets (NP) have been used to prevent vasospasm in patients with subarachnoid hemorrhage (SAH)." | 5.15 | Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo. ( Kasuya, H, 2011) |
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 5.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 5.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAH patients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale)." | 4.88 | Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. ( He, GH; Liu, GJ; Liu, Y; Luo, GJ; Wang, XL; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ, 2012) |
| "The incidence of convulsion and associated factors were retrospectively analyzed in 23 patients with symptomatic cerebral vasospasm following subarachnoid hemorrhage (SAH) who underwent a total of 31 intra-arterial infusion of fasudil hydrochloride (IAFH) procedures in 49 vessels." | 3.76 | Convulsion during intra-arterial infusion of fasudil hydrochloride for the treatment of cerebral vasospasm following subarachnoid hemorrhage. ( Enomoto, Y; Iwama, T; Yamada, K; Yoshimura, S, 2010) |
| "Using CT perfusion studies we evaluated changes in the cerebral circulation before and after the intravenous administration of fasudil 60 mg in 8 patients 7 to 14 days after a subarachnoid hemorrhage." | 3.73 | [Cerebral circulation dynamics following fasudil intravenous infusion: a CT perfusion study]. ( Ono, K; Shirotani, T; Yamana, D; Yuba, K, 2005) |
| "The cerebral circulatory dynamics were evaluated before and after intra-arterial administration of fasudil hydrochloride in 20 patients with angiographic vasospasm after subarachnoid hemorrhage (SAH)." | 3.73 | Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage - analysis of time-density curve with digital subtraction angiography. ( Hayashi, M; Iwabuchi, S; Samejima, H; Ueda, M; Uehara, H; Yokouchi, T, 2006) |
| "The authors report a case of convulsion during intra-arterial selective infusion of fasudil hydrochloride (FSD) for treatment of vasospasm following subarachnoid hemorrhage (SAH)." | 3.72 | [A case of convulsion during selective intra-arterial infusion of fasudil hydrochloride for treatment of vasospasm following subarachnoid hemorrhage]. ( Date, I; Nakashimia, H; Ohmoto, T; Ono, S; Sasahara, W; Sugiu, K; Tokunaga, K, 2004) |
| "To investigate the safety and efficacy of liposomal fasudil in a sustained-release form for the prevention of cerebral vasospasm after subarachnoid hemorrhage (SAH)." | 3.71 | Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. ( Ishida, T; Kiwada, H; Meguro, T; Takanashi, Y; Yamamoto, I; Zhang, JH, 2001) |
| "To date, the pharmacologic approach to cerebral vasospasm and ischemia has been hampered in part by an inability to attain sufficiently high concentrations of drugs in the cerebrospinal fluid (CSF)." | 2.42 | [Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia]. ( Ishida, T, 2004) |
| "Chronic cerebral vasospasm was produced using a two-hemorrhage canine model." | 1.38 | Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. ( Asano, T; Hitomi, A; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M; Takayasu, M; Yano, K, 2012) |
| " The occurrence of adverse events, occurrence of low density areas associated with vasospasm on computed tomography, absence of symptomatic vasospasm, and poor clinical outcomes associated with vasospasm were compared between the fasudil and fasudil plus ozagrel groups." | 1.35 | Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. ( Satoh, S; Seto, M; Shibuya, M; Sugiyama, H; Suzuki, Y; Takakura, K, 2008) |
| "Symptomatic cerebral vasospasm is a major cause of disability and death in patients with aneurysmal subarachnoid hemorrhage." | 1.33 | Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride. ( Kohmura, E; Kota, M; Kuwamura, K; Minami, H; Tanaka, K, 2005) |
| "Fasudil hydrochloride was administered via the internal carotid artery without selective microcatheterization, at a concentration and speed of 30 mg/20 ml/10-15 min, using a total dose of 30-60 mg." | 1.33 | [Intra-arterial administration of fasudil hydrochloride: duration of action]. ( Matsushita, Y; Ono, K; Shirotani, T; Takahara, T; Wada, K; Yamana, D; Yuba, K, 2005) |
| "Cerebral vasospasm is a potentially fatal consequence of aneurysmal subarachnoid hemorrhage and influences the prognosis of the patient." | 1.31 | Thin and thick filament regulation of contractility in experimental cerebral vasospasm. ( Butler, WE; Kim, I; Leinweber, BD; Morgalla, M; Morgan, KG; Peterson, JW; Sasaki, Y; Seto, M, 2000) |
| "This new approach for cerebral vasospasm may have significant potential for use in the clinical setting." | 1.31 | Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats. ( Allen, TM; Ishida, T; Kirchmeier, MJ; Meguro, T; Takanashi, Y; Zhang, JH, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 19 (54.29) | 29.6817 |
| 2010's | 15 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naraoka, M | 1 |
| Munakata, A | 1 |
| Matsuda, N | 1 |
| Shimamura, N | 1 |
| Ohkuma, H | 1 |
| Liu, J | 1 |
| Yao, GE | 1 |
| Zhou, HD | 1 |
| Jiang, XJ | 1 |
| Xie, P | 1 |
| Iwabuchi, S | 3 |
| Hayashi, M | 3 |
| Yokouchi, T | 3 |
| Sato, K | 2 |
| Nakayama, H | 2 |
| Harashina, J | 2 |
| Iwama, J | 1 |
| Ishii, M | 1 |
| Hiramoto, Y | 1 |
| Hirai, N | 1 |
| Hirata, Y | 2 |
| Saito, N | 2 |
| Ito, K | 2 |
| Kimura, H | 2 |
| Aoki, K | 2 |
| Saito, A | 1 |
| Inoue, M | 1 |
| Kon, H | 1 |
| Imaruoka, S | 1 |
| Basaki, K | 1 |
| Midorikawa, H | 1 |
| Sasaki, T | 1 |
| Nishijima, M | 1 |
| Suzuki, Y | 2 |
| Shibuya, M | 4 |
| Satoh, S | 3 |
| Sugiyama, H | 1 |
| Seto, M | 4 |
| Takakura, K | 2 |
| Enomoto, Y | 1 |
| Yoshimura, S | 1 |
| Yamada, K | 1 |
| Iwama, T | 1 |
| Pierot, L | 1 |
| Aggour, M | 1 |
| Moret, J | 1 |
| Hansen-Schwartz, J | 1 |
| Kasuya, H | 1 |
| Akahata, M | 1 |
| Ishihara, M | 1 |
| Yamanaka, K | 1 |
| Nakajima, S | 1 |
| Yamasaki, M | 1 |
| Alford, PW | 1 |
| Dabiri, BE | 1 |
| Goss, JA | 1 |
| Hemphill, MA | 1 |
| Brigham, MD | 1 |
| Parker, KK | 1 |
| Liu, GJ | 1 |
| Wang, ZJ | 1 |
| Wang, YF | 1 |
| Xu, LL | 1 |
| Wang, XL | 1 |
| Liu, Y | 1 |
| Luo, GJ | 1 |
| He, GH | 1 |
| Zeng, YJ | 1 |
| Asano, T | 3 |
| Zhao, J | 2 |
| Zhou, D | 2 |
| Guo, J | 2 |
| Ren, Z | 2 |
| Zhou, L | 2 |
| Wang, S | 2 |
| Zhang, Y | 1 |
| Xu, B | 3 |
| Zhao, K | 1 |
| Wang, R | 2 |
| Mao, Y | 1 |
| Zhang, X | 1 |
| Takayasu, M | 1 |
| Kawasaki, K | 1 |
| Ikegaki, I | 1 |
| Hitomi, A | 1 |
| Yano, K | 1 |
| Groom, CR | 1 |
| Hopkins, AL | 1 |
| Sasahara, W | 1 |
| Ono, S | 1 |
| Tokunaga, K | 1 |
| Sugiu, K | 1 |
| Nakashimia, H | 1 |
| Date, I | 1 |
| Ohmoto, T | 1 |
| Ishida, T | 4 |
| Tanaka, K | 1 |
| Minami, H | 1 |
| Kota, M | 1 |
| Kuwamura, K | 1 |
| Kohmura, E | 1 |
| Ono, K | 2 |
| Shirotani, T | 2 |
| Wada, K | 1 |
| Takahara, T | 1 |
| Matsushita, Y | 1 |
| Yuba, K | 2 |
| Yamana, D | 2 |
| Fuse, T | 1 |
| Umezu, M | 1 |
| Yamamoto, M | 1 |
| Demura, K | 1 |
| Nishikawa, Y | 1 |
| Niwa, Y | 1 |
| Uehara, H | 1 |
| Ueda, M | 1 |
| Samejima, H | 1 |
| Sugimoto, Y | 1 |
| Nishizawa, S | 1 |
| Zhang, JH | 4 |
| Takuwa, Y | 1 |
| Sasaki, Y | 3 |
| Kim, I | 1 |
| Leinweber, BD | 1 |
| Morgalla, M | 1 |
| Butler, WE | 1 |
| Peterson, JW | 1 |
| Morgan, KG | 1 |
| Takanashi, Y | 3 |
| Meguro, T | 3 |
| Kiwada, H | 1 |
| Yamamoto, I | 1 |
| Tanaka, Y | 1 |
| Masuzawa, T | 1 |
| Saito, M | 1 |
| Yamada, T | 1 |
| Ebihara, A | 1 |
| Iwasa, H | 1 |
| Mori, S | 1 |
| Masaoka, H | 1 |
| Takasato, Y | 1 |
| Nojiri, T | 1 |
| Hayakawa, T | 1 |
| Akimoto, H | 1 |
| Yatsushige, H | 1 |
| Toumori, H | 1 |
| Miyazaki, Y | 1 |
| Honma, M | 1 |
| Kirchmeier, MJ | 2 |
| Allen, TM | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study[NCT01996436] | Phase 4 | 330 participants (Anticipated) | Interventional | 2016-08-29 | Recruiting | ||
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Angiospasm, Intracranial
| Article | Year |
|---|---|
Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angioplasty, Balloon; Critical Care; Endovascular Pro | 2010 |
Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Cerebral Infarction; Humans; Middle Aged; Prot | 2012 |
[Rho-kinase inhibitors].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Clinical Trials as Topic; Coronary A | 2011 |
[Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Delayed-Action Preparations; | 2004 |
[Basic research and treatment for cerebral vasospasm after subarachnoid hemorrhage: the present and future prospects].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Angioplasty, Balloon; Calcium Channel | 2008 |
[The molecular mechanism of vasospasm and the attenuation by fasudil].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Humans; Myosin Light Chains; Phosphorylation; Vasocon | 1999 |
Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Enzyme Inhibitors; Humans; Injections, Intra | 2001 |
4 trials available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Angiospasm, Intracranial
| Article | Year |
|---|---|
Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Calcium Channel Blockers; Cooperative Be | 2011 |
Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Brain Ischemia; Calcium Channel Blockers | 2011 |
Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Brain Ischemia; Female; Humans; Male; Middle A | 2006 |
A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Aged; Cohort Studies; Female; Huma | 2007 |
24 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Angiospasm, Intracranial
| Article | Year |
|---|---|
Suppression of the Rho/Rho-kinase pathway and prevention of cerebral vasospasm by combination treatment with statin and fasudil after subarachnoid hemorrhage in rabbit.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Drug Combinations; Enzyme-Li | 2013 |
Clinical investigation of fasudil for the prevention of cerebral vasospasm in extracranial carotid artery stenting.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Calcium Channel Blockers; Carotid Arteries; Cer | 2014 |
Prophylactic intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid haemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Combined Modality The | 2015 |
Effectiveness of intraarterial administration of fasudil hydrochloride for preventing symptomatic vasospasm after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiography, Digital Subtraction; Blood Circulation T | 2015 |
Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Drug Therapy, Combination; Enzyme Inhibitors; F | 2008 |
Convulsion during intra-arterial infusion of fasudil hydrochloride for the treatment of cerebral vasospasm following subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Anticonvulsants; Cath | 2010 |
Advances in treatment of cerebral vasospasm: an update.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calcium Channel Blockers; Clinical Trials as Topic; H | 2011 |
Intra-arterial Administration of Fasudil Hydrochloride for Vasospasm Following Subarachnoid Haemorrhage: Experience of 90 Cases.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calcium Channel Blockers; Cerebral Angiography; Femal | 2011 |
Intracranial hemorrhage after intra-arterial administration of fasudil for treatment of cerebral vasospasm following subarachnoid hemorrhage: a serious adverse event.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Cerebral Angiography; Embolization, Therapeutic; Fata | 2012 |
Blast-induced phenotypic switching in cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Arteries; Blast Injuries; Blotting, Weste | 2011 |
Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Viscosity; Brain Ischemia; Disease Mod | 2012 |
Protein kinase drugs--optimism doesn't wait on facts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Drug Design; Enzyme Inhibitors; Humans; Protein Kinas | 2002 |
[A case of convulsion during selective intra-arterial infusion of fasudil hydrochloride for treatment of vasospasm following subarachnoid hemorrhage].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; | 2004 |
Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Female; Humans; Infus | 2005 |
[Intra-arterial administration of fasudil hydrochloride: duration of action].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Carotid Artery, Internal; Cerebral Arteries; Ce | 2005 |
[Cerebral circulation dynamics following fasudil intravenous infusion: a CT perfusion study].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Brain; Cerebrovascular Circulation; Fema | 2005 |
External carotid artery aneurysm developing after embolization of a ruptured posterior inferior cerebellar artery aneurysm in a patient with cervicocephalic fibromuscular dysplasia--case report.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aneurysm, Ruptured; Angiography, Digital Subtr | 2006 |
Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage - analysis of time-density curve with digital subtraction angiography.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Angiography, Digital Subtraction; Brain; | 2006 |
Thin and thick filament regulation of contractility in experimental cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Basilar Artery; Calcium-Binding Prot | 2000 |
Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Dogs; Dose-Response Relation | 2001 |
Combined administration of Fasudil hydrochloride and nitroglycerin for treatment of cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Brain Ischemia; Drug Combinations; Female; Huma | 2001 |
Clinical effect of Fasudil hydrochloride for cerebral vasospasm following subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Cerebral Angiography; | 2001 |
A novel drug delivery system as prophylaxis for cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Delayed-Action Preparations; | 2001 |
Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Drug Delivery Systems; Injec | 2001 |